Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $7.4 million.

  • Nurix Therapeutics' Other Non-Current Assets rose 718.53% to $7.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was $7.4 million, marking a year-over-year increase of 718.53%. This contributed to the annual value of $3.2 million for FY2024, which is 17.37% down from last year.
  • As of Q3 2025, Nurix Therapeutics' Other Non-Current Assets stood at $7.4 million, which was up 16.38% from $6.3 million recorded in Q2 2025.
  • Over the past 5 years, Nurix Therapeutics' Other Non-Current Assets peaked at $7.4 million during Q3 2025, and registered a low of $901,000 during Q1 2022.
  • Its 3-year average for Other Non-Current Assets is $2.9 million, with a median of $901,000 in 2024.
  • In the last 5 years, Nurix Therapeutics' Other Non-Current Assets skyrocketed by 1,680.54% in 2021 and then tumbled by 72.65% in 2022.
  • Nurix Therapeutics' Other Non-Current Assets (Quarterly) stood at $2.8 million in 2021, then tumbled by 68.20% to $901,000 in 2022, then surged by 324.31% to $3.8 million in 2023, then dropped by 17.37% to $3.2 million in 2024, then surged by 718.53% to $7.4 million in 2025.
  • Its Other Non-Current Assets was $7.4 million in Q3 2025, compared to $6.3 million in Q2 2025 and $5.6 million in Q1 2025.